AKBA - Akebia Therapeutics, Inc.
7.49 0.00 (0.00%)
After hours: 6:51PM EST
| Previous Close | 7.78 |
| Open | 7.76 |
| Bid | 7.36 x 1000 |
| Ask | 10.50 x 800 |
| Day's Range | 7.29 - 7.93 |
| 52 Week Range | 7.29 - 16.43 |
| Volume | 562,278 |
| Avg. Volume | 502,630 |
| Market Cap | 427.373M |
| Beta (3Y Monthly) | 2.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.37 |
| Earnings Date | Nov 12, 2018 - Nov 16, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.63 |
GuruFocus.com•11 hours agoDavid Abrams Buys 3 Stocks in 3rd Quarter
David Abrams (Trades, Portfolio), the leader of Abrams Capital Management, released his third-quarter portfolio last week, listing three new holdings. Warning! GuruFocus has detected 7 Warning Signs with SHPG.
- Business Wire•yesterday
Akebia Therapeutics Sends Letter to Shareholders
Akebia Therapeutics, Inc. (AKBA) mailed a letter to Akebia shareholders in connection with the special meeting of Akebia shareholders (the “Special Meeting”) that has been called to approve shareholder proposals relating to the previously announced proposed merger of Akebia and Keryx Biopharmaceuticals. The Akebia Board of Directors unanimously recommends that Akebia shareholders vote “FOR” the proposals relating to the proposed merger with Keryx. The Special Meeting to approve our proposed merger with Keryx is approaching.
- Zacks•6 days ago
Akebia Therapeutics (AKBA) Reports Q3 Loss, Tops Revenue Estimates
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 40.26% and 33.88%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•6 days ago
Akebia Therapeutics: 3Q Earnings Snapshot
The Cambridge, Massachusetts-based company said it had a loss of 46 cents per share. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
- Business Wire•6 days ago
Akebia Therapeutics Announces Third Quarter 2018 Financial Results
Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced financial results for the third quarter ended September 30, 2018. “In the third quarter, we continued to drive our vadadustat Phase 3 development program, while working diligently to close our proposed merger transaction with Keryx Biopharmaceuticals by the end of 2018. The combination is expected to create a fully-integrated kidney disease therapeutics company, with a strengthened financial profile, positioned to deliver substantial long-term value to shareholders,” said John P. Butler, President and Chief Executive Officer of Akebia Therapeutics.
- Zacks•7 days ago
Analysts Estimate Akebia Therapeutics (AKBA) to Report a Decline in Earnings: What to Look Out for
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire•12 days ago
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), granted four newly-hired employees options to purchase an aggregate of 25,400 shares of Akebia’s common stock on October 31, 2018, as inducements material to each such employee’s entering into employment with Akebia. The options have an exercise price of $7.49 per share, which is equal to the closing price of Akebia’s common stock on the grant date. Each stock option vests over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee’s continued service with the company.
- Business Wire•15 days ago
Akebia Therapeutics Files Definitive Proxy Statement in Connection with Proposed Merger with Keryx Biopharmaceuticals
Akebia Therapeutics, Inc. (AKBA) today announced that it and Keryx Biopharmaceuticals, Inc. (KERX) filed a definitive joint proxy statement with the U.S. Securities and Exchange Commission (“SEC”) in connection with their respective special meetings of shareholders that have been called to approve shareholder proposals relating to the previously announced proposed merger of Akebia and Keryx. Akebia is mailing a letter together with its proxy materials to Akebia shareholders in connection with the special meeting of Akebia shareholders (the “Special Meeting”).
- GlobeNewswire•15 days ago
Keryx Biopharmaceuticals Announces Filing of Definitive Joint Proxy Statement in Connection with Pending Merger with Akebia Therapeutics
Keryx Biopharmaceuticals, Inc. (KERX) today announced that it and Akebia Therapeutics, Inc. (AKBA) have filed definitive proxy materials with the U.S. Securities and Exchange Commission (“SEC”) in connection with their respective Special Meetings of Stockholders that have been called to approve the previously announced proposed merger of Keryx and Akebia. The definitive joint proxy statement is available on the Investor Relations section of Keryx’s website, as well as www.sec.gov, and will be mailed to all Keryx common stockholders entitled to vote at the Special Meeting.
- GlobeNewswire•27 days ago
Report: Developing Opportunities within VICI Properties, Transocean, Akebia Therapeutics, Welltower, Golden Star Resources, and Casa — Future Expectations, Projections Moving into 2018
NEW YORK, Oct. 19, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Business Wire•last month
Akebia Therapeutics Announces Presentations at the American Society of Nephrology Kidney Week 2018 Annual Meeting
Akebia Therapeutics, Inc. , a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor , today announced two posters to be presented at the upcoming American Society of Nephrology Kidney Week 2018 Annual Meeting in San Diego, California, from October 23 to 28, 2018.
- Business Wire•last month
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), granted six newly-hired employees options to purchase an aggregate of 32,750 shares of Akebia’s common stock on September 28, 2018, as inducements material to each such employee’s entering into employment with Akebia. The options have an exercise price of $8.83 per share, which is equal to the closing price of Akebia’s common stock on the grant date. Each stock option vests over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee’s continued service with the company.
- Zacks•last month
Endo Recalls 2 Lots of Robaxin Tablets Due to Labeling Error
Endo International (ENDP) recalls two lots of Robaxin 750mg Tablets due to wrong dosing information on the label.
- Business Wire•2 months ago
Akebia Therapeutics to Participate in Upcoming Investor Conferences
Akebia Therapeutics, Inc. , a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-indu
- Simply Wall St.•2 months ago
What Investors Should Know About Akebia Therapeutics Inc’s (NASDAQ:AKBA) Financial Strength
Zero-debt allows substantial financial flexibility, especially for small-cap companies like Akebia Therapeutics Inc (NASDAQ:AKBA), as the company does not have to adhere to strict debt covenants. However, it also facesRead More...
- Business Wire•2 months ago
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), granted a newly-hired employee options to purchase an aggregate of 1,250 shares of Akebia’s common stock on August 31, 2018, as inducements material to such employee’s entering into employment with Akebia. The options have an exercise price of $8.21 per share, which is equal to the closing price of Akebia’s common stock on the grant date. Each stock option vests over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee’s continued service with the company.
- Business Wire•2 months ago
Akebia Therapeutics to Participate in Upcoming Investor Conferences
Akebia Therapeutics, Inc. , a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor , today announced that John P.
- InvestorPlace•3 months ago
5 Healthcare Stocks That Are Down, But Not Out!
Few investment sectors arouse sharply divided opinion quite like healthcare stocks. This segment features incredible volatility as poor clinical trials could devastate individual companies. During the campaign trail for the 2016 presidential election, then-real-estate-mogul Donald Trump lashed out against pharmaceuticals.
- Business Wire•3 months ago
Akebia Therapeutics Appoints Cynthia Smith to Its Board of Directors
Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced the appointment of Cynthia Smith to its Board of Directors. Cynthia Smith has more than 20 years of broad leadership experience within the healthcare industry.
- GlobeNewswire•3 months ago
Report: Exploring Fundamental Drivers Behind Oaktree Specialty Lending, uniQure N.V, Mercury, Akebia Therapeutics, Mitel Networks, and Greenlight Capital Re — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Aug. 21, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Oaktree ...
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of AKBA earnings conference call or presentation 8-Aug-18 8:30pm GMT
Q2 2018 Akebia Therapeutics Inc Earnings Call
- Zacks•3 months ago
Keryx's (KERX) Loss Wider Than Expected in Q2, Sales Lag
Keryx (KERX) posts wider-than-expected loss in Q2. Moreover, revenues miss the mark.
- Benzinga•3 months ago
The Daily Biotech Pulse: Ampio Slides On Offering, Sangamo's Positive Trial Results, Insys Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 8) AstraZeneca plc (ADR) (NYSE: AZN ) Bio-Rad Laboratories, Inc. ...
- Zacks•3 months ago
Akebia Therapeutics (AKBA) Reports Q2 Loss, Tops Revenue Estimates
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -15.38% and 0.09%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•3 months ago
Akebia Therapeutics: 2Q Earnings Snapshot
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 60 cents. The kidney disease treatment developer posted revenue of $48.8 million in the period. Akebia Therapeutics ...
